{"id":"NCT00538434","sponsor":"Ception Therapeutics","briefTitle":"Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years","officialTitle":"An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-03","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2007-10-02","resultsPosted":"2016-09-02","lastUpdate":"2016-09-02"},"enrollment":227,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Eosinophilic Esophagitis"],"interventions":[{"type":"BIOLOGICAL","name":"Reslizumab","otherNames":["CTx55700","Cinquilâ„¢","CEP-38072"]},{"type":"OTHER","name":"Saline","otherNames":[]}],"arms":[{"label":"Reslizumab 1 mg/kg","type":"EXPERIMENTAL"},{"label":"Reslizumab 2 mg/kg","type":"EXPERIMENTAL"},{"label":"Reslizumab 3 mg/kg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This trial will study three doses of reslizumab versus placebo in children with eosinophilic esophagitis (EE). The objectives of the trial will be to study the effectiveness of reslizumab in improving the clinical signs and symptoms and reducing esophageal eosinophils as well as assessing the safety profile compared to placebo.","primaryOutcome":{"measure":"Mean Percent Change From Baseline to End of Treatment in Peak Esophageal Eosinophil (EE) Levels","timeFrame":"Baseline, End of Treatment (up to 15 weeks [+/- 4 days])","effectByArm":[{"arm":"Reslizumab 1 mg/kg","deltaMin":-37.6,"sd":70.86},{"arm":"Reslizumab 2 mg/kg","deltaMin":-58.27,"sd":35.45},{"arm":"Reslizumab 3 mg/kg","deltaMin":-56.46,"sd":34.82},{"arm":"Placebo","deltaMin":11.5,"sd":91.42}],"pValues":[{"comp":"OG000 vs OG003","p":"< 0.0001"},{"comp":"OG001 vs OG003","p":"< 0.0001"},{"comp":"OG002 vs OG003","p":"< 0.0001"}]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":37,"countries":["United States","Canada"]},"refs":{"pmids":["22206777"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":55},"commonTop":["HEADACHE","COUGH","NASAL CONGESTION","PHARYNGOLARYNGEAL PAIN","UPPER RESPIRATORY TRACT INFECTION"]}}